Helixgate

Helixgate

Uncategorized

Novo’s late-stage sickle cell win piles pressure on competitors

Published

on

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Merck partner reveals bispecific data; Biogen pays $100M for antibody rights

Published

on

Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of the drug, known as MK-2010, while four of nine patients …

Continue Reading

Uncategorized

STAT+: The PBMs fight back, and arbitration doesn’t lose

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Did you know it’s National Library Week? Of course you did, you look so studious. To honor the thrill of reading and learning, STAT is offering 60% off our subscription for your first year. Check it out, visit a library, and as always, say hello: bob.herman@statnews.com.

A contentious fight over drug price transparency

Anna Yeo/STAT

The phalanx of lobbyists representing pharmacy benefit managers and health insurers has mounted stiff opposition to a federal proposal that attempts to pry open the black box of prescription drug prices.

Continue to STAT+ to read the full story…

Read More

Published

on

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Did you know it’s National Library Week? Of course you did, you look so studious. To honor the thrill of reading and learning, STAT is offering 60% off our subscription for your first year. Check it out, visit a library, and as always, say hello: bob.herman@statnews.com.

A contentious fight over drug price transparency

Anna Yeo/STAT

The phalanx of lobbyists representing pharmacy benefit managers and health insurers has mounted stiff opposition to a federal proposal that attempts to pry open the black box of prescription drug prices.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment

Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment

Published

on

LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in central London and investing £150 million over the next 10 years.

The AI hub will be …​ ​Read More

Continue Reading
Advertisement

Trending